Text this: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 __   _    __   __  __    __   __   __    ____    
| || | ||  \ \\/ // \ \\ / //  \ \\/ //  |  _ \\  
| '--' ||   \ ` //   \ \/ //    \ ` //   | |_| || 
| .--. ||    | ||     \  //      | ||    | .  //  
|_|| |_||    |_||      \//       |_||    |_|\_\\  
`-`  `-`     `-`'       `        `-`'    `-` --`